Peter R. Carroll MD MPH

Urology•San Francisco, CA

Surgical Oncology

Ken and Donna Derr - Chevron Distinguished Professor Taube Family Distinguished Professor UCSF Department of Urology

Join to View Full Profile

1825 4th StSan Francisco, CA 94143
Phone+1 415-353-7171
Fax+1 415-514-6195

Education & Training

New York Presbyterian Hospital (Cornell Campus)Residency, Urology, 1984 - 1986
University of California (San Francisco)Residency, Urology, 1981 - 1984
University of California (San Francisco)Residency, Surgery, 1979 - 1981
Georgetown University School of MedicineClass of 1979

Certifications & Licensure

NY State Medical License 1984 - Present
CA State Medical License 1980 - 2025
American Board of Urology Urology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
America's Top Doctors for Cancer Castle Connolly, 2005-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Super Doctor SuperDoctors.com
Top MD Consumers Checkbook
Fellow (FACS) American College of Surgeons
Join now to see all

Clinical Trials

Surgery With or Without Chemotherapy in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer Start of enrollment: 1996 Dec 01
Unknown status
Phase 3
Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Start of enrollment: 2004 Feb 01
Completed
Phase 3
Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer Start of enrollment: 2003 Apr 01
Completed
Not Applicable
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab Start of enrollment: 2008 Apr 01
Terminated
Phase 3
Nutrition and Lifestyle Changes in Patients With Previously Untreated Stage I or Stage II Prostate Cancer Start of enrollment: 2003 Sep 01
Completed
Not Applicable
Prostate Active Surveillance Study
RECRUITING
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
ACTIVE_NOT_RECRUITING
PHASE3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RECRUITING
A Study of Intra-operative Autologous Retropubic Urethral Sling on Urinary Control After Robot Assisted Radical Prostatectomy Start of enrollment: 2013 Apr 01
Completed
Not Applicable
Streamlining Trauma Research Evaluation With Advanced Measurement Start of enrollment: 2014 Jan 01
Completed
Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial) Start of enrollment: 2015 Mar 23
RECRUITING
PHASE3
Decision Support Tools for Men With Prostate Cancer- Clinical & Lifestyle Model Start of enrollment: 2015 Mar 25
Completed
Not Applicable
Web-based Lifestyle Trial Among Men With Prostate Cancer: Prostate 8 Start of enrollment: 2015 Jun 01
Completed
Not Applicable
CHAMP: A Randomized Controlled Trial of High-intensity Aerobic and Resistance Exercise for Metastatic Prostate Cancer Start of enrollment: 2016 Jul 18
Completed
Not Applicable
[18F]FTC-146 PET/MRI in Healthy Volunteers and in CRPS and Sciatica Start of enrollment: 2016 Feb 09
Completed
Early Phase 1
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer Start of enrollment: 2016 Nov 01
Completed
Phase 2, Phase 3
Join now to see all

Publications & Presentations

PubMed

Determining Long-term Prostate Cancer Outcomes for Active Surveillance Patients Without Early Disease Progression: Implications for Slowing or Stopping Surveillance.
Kevin Shee, James Nie, Janet E Cowan, Lufan Wang, Samuel L Washington 3rd
European Urology Oncology. 2025-04-01
2 citations
Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry.
Chris Bangma, Paul Doan, Lin Zhu, Sebastiaan Remmers, Daan Nieboer
European Urology Oncology. 2025-04-01
1 citations
De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium.
Yoichiro Tohi, John M Sahrmann, Jaron Arbet, Takuma Kato, Lui Shiong Lee
European Urology Oncology. 2025-04-01

Journal Articles

First-in-Human Phase I Study of CTT1057, a Novel 18F Labeled Imaging Agent with Phosphoramidate Core Targeting Prostate Specific Membrane Antigen in Prostate Cancer
Spencer C Behr, Hao G Nguyen, Thomas A Hope, Kirsten L Greene, Matthew R Cooperberg, Robert R Flavell, Eric J Small, Peter R Carroll, Journal of Nuclear Medicine

Lectures

AUA Education Workshop for Program Directors and Chairpersons
American Urological Association, Linthicum, Maryland - 2/9/2013

Press Mentions

Improving Prostate Cancer Screening for Transgender WomenJune 26th, 2024
Transgender Women Are Still at Risk for Prostate CancerApril 30th, 2023
New PET Imaging Agent Alters Prostate Cancer Plan for More Than 40% of PatientsSeptember 10th, 2021
Join now to see all

Grant Support

Effectiveness Of Early Stage Prostate Cancer TreatmentNational Cancer Institute2009–2010
MALE Reproductive Health Research Career Development ProgramEunice Kennedy Shriver National Institute Of Child Health &Human Development2006–2010
UCSF Prostate Cancer SporeNational Cancer Institute2004–2008
Molecular Effects Of Nutrition Supplements In ProstateNational Cancer Institute2005–2007
Active Surveillance For Early Stage Prostate Cancer: Selection, MonitoringNational Cancer Institute2006